1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs from NIDDK are competitive federal grant programs administered by the National Institute of Diabetes and Digestive and Kidney Diseases supporting innovative research by small businesses with potential for commercialization.
NIDDK participates in both SBIR and STTR programs, with funding opportunities aligned to its mission areas in diabetes, digestive diseases, and kidney diseases. Eligible applicants are U.S. small businesses with innovative research applicable to NIDDK's scientific program areas. The NIH SEED website provides comprehensive application guidance and NIDDK-specific program contacts.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Small Business Programs - NIDDK Research Programs & Contacts The National Institute of Diabetes and Digestive and Kidney Diseases participates in the Small Business Innovation Research ( SBIR ) and Small Business Technology Transfer ( STTR ) programs. These programs support innovative research conducted by small businesses that has the potential for commercialization.
The NIH Small business Education and Entrepreneurial Development (SEED) website provides comprehensive information about small business funding. This site includes information on the basics of the SBIR and STTR programs and step-by-step instructions about the SBIR and STTR application process , and hosts the NIDDK-specific small business program information .
NIDDK information includes: Scientific Program Areas including Program Staff contacts and example projects from three extramural divisions of the NIDDK on the programs at the NIDDK Frequently Asked Questions Please review the NIDDK information and contact the appropriate NIDDK Small Business Program Staff contact if you have any questions.
Small Business Technology Transfer Grant (STTR) Small Business Innovation Research Grant (SBIR) SBIR/STTR Form Registration Page
According to the current listing, eligibility includes: Small businesses with innovative research that has potential for commercialization, applicable to NIDDK mission areas. Confirm the full requirements in the official notice before applying.
Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs (NIDDK) is funded by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the NIH. Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional) is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the NIH. This program encourages applications to plan multi-center clinical studies. While not specific to bioartificial kidneys, research planning for such complex medical devices would fall under clinical study implementation.
NIDDK High Risk, High Impact Research is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the NIH. NIDDK supports high-risk, high-impact research to advance understanding and treatment of kidney diseases. Development of a bioartificial kidney would be considered high-impact research. This would likely be pursued through general NIH funding mechanisms (e.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article